The Feasibility of Dynamic Liquid Biopsy Monitoring During Neoadjuvant Treatment for EGFR-mutated NSCLC
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorZhejiang University
About this trial
This study aimed to assess the value of dynamic ctDNA monitoring in guiding the development of personalized neoadjuvant treatment strategies for EGFR-mutated NSCLC patients.
Eligibility criteria
Qualifiers
Patients should voluntarily join this study and sign the informed consent form
Patients diagnosed with resectable stage II-IIIB (T1-4N0-2M0, excluding T4 with invasion of vital structures and bulky or infiltrative N2) NSCLC
Patients with EGFR 19del or L858R mutations.
Age from 18 to 75 years old, both male and female
Disqualifiers
Patients with other primary malignancies within the past 3 years (excluding cured skin basal cell carcinoma and cervical carcinoma in situ)
Patients with active hepatitis B/C
Patients with any active autoimmune diseases or a history of autoimmune diseases
Patients who are using immunosuppressive agents or require systemic hormone therapy
Trial design
Treatments tested in this trial
- ctDNA monitoring
Treatment groups
300 Participants
are divided into 4 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov